Technology News and Research

RSS

New article published in Journal of Surgical Research highlights PACE technology

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today announced that an article titled "Microvascular Response to Shock Wave Application in Striated Skin Muscle" was recently published in the on-line edition of the Journal of Surgical Research.

4 Aug 2010

MMRSS expands to Taiwan, Hong Kong and Singapore

MMRSS, which has been expanding its geographic footprint over the past 5 years, announced the opening of new full service offices in Taiwan, Hong Kong and Singapore.

4 Aug 2010

Targacept licenses Cornerstone technology for inflammatory disorders program

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has added to its program for inflammatory disorders by entering into an exclusive worldwide license agreement with Cornerstone Therapeutics Inc. The agreement grants Targacept rights to Cornerstone's NNR-based patents, as well as its library of preclinical compounds that act on the alpha7 or other nicotinic receptors.

4 Aug 2010

Bill Gates to keynote at 2010 mHealth Summit

Bill Gates, Co-Chair and Trustee of the Bill & Melinda Gates Foundation, will provide a keynote address on the opportunity of mobile technologies to improve health outcomes in the developing world at the 2010 mHealth Summit, the summit organizers announced today. The summit, organized by the Foundation for the National Institutes of Health in partnership with the National Institutes of Health (NIH) and the mHealth Alliance, will be held November 8-10 in Washington, DC.

4 Aug 2010

GenSpera acquires patent application for medical imaging technology

GenSpera, Inc. announced that it has acquired a patent application from the Johns Hopkins University and the University of Copenhagen for technology relating to medical imaging. The technology incorporates derivatives of thapsigargin, the active ingredient in GenSpera's therapeutics program, coupled with its patented tumor-targeted peptides, to create cancer-specific imaging compounds.

4 Aug 2010

Savient second-quarter net loss decreases to $5.0 million

Savient Pharmaceuticals, Inc. reported financial results for the three and six months ended June 30, 2010. The net loss for the second quarter of 2010 was $5.0 million, or $0.07 per basic and diluted share, on total revenues of $1.0 million, compared with a net loss of $54.8 million, or $0.92 per basic and diluted share on total revenues of $0.7 million for the second quarter of 2009.

4 Aug 2010

Invivo recognized with 2010 Gold Medical Design Excellence Award

On June 9, 2010, Invivo was recognized with a 2010 Gold Medical Design Excellence Award for its DynaCAD for Prostate and DynaTRIM (Trans-Rectal Interventional MRI) clinical solutions. The MDEA awards ceremony took place in early June at New York City's Jacob K. Javits Convention Center where gold and silver winners were honored.

4 Aug 2010

Special issue on new developments in vestibular rehabilitation

Rehabilitation is essential for patients with disabling symptoms of dizziness, vertigo, and unsteadiness caused by disorders of the vestibular system. A special issue of The Journal of Neurologic Physical Therapy (JNPT) presents an update on new and emerging vestibular rehabilitation techniques, highlighting the physical therapist's role on the multidisciplinary teams providing patient care and research.

4 Aug 2010

Ties between global health, national security, jobs emphasized at recent meeting in Washington State

The message that U.S. investment in global health "helps advance longer term security and development goals" while also supporting a "small but growing industry with good paying jobs and world class research" was the focus of a recent meeting between officials from Washington, D.C. and Washington State, the Seattle Times' "Business of Giving" blog writes.

4 Aug 2010

Siteman Cancer Center to test radiotherapy system from ViewRay

Researchers at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, a national leader in the early adoption and use of advanced treatments for cancer patients, will soon become the first in the world to test an innovative radiotherapy system from ViewRay, Inc. The ViewRay system is designed to improve the accuracy of cancer treatments through a combination of medical imaging and radiotherapy delivery.

4 Aug 2010

Merck-Chimie to commercialize CardioGenics' proprietary paramagnetic beads

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that CardioGenics Inc. and Merck Chimie S.A.S. have agreed on a plan to commercialize CardioGenics' proprietary paramagnetic beads, with shipments to Merck-Chimie's customers scheduled to start mid-September 2010.

4 Aug 2010

Proton therapy to treat patient’s tumor without compromising quality of life

The radiation oncologist's mantra is to deliver the maximum dose of radiation to the malignant tumor, while limiting damage to healthy surrounding tissue. In proton therapy, this balance is achieved by using proton particles, accelerated to nearly the speed of light, to mimic the shape of a tumor and effectively deposit their energy within the confines of it with sub-millimeter precision.

4 Aug 2010

Victory Pharma acquires assets of MiddleBrook Pharmaceuticals

Victory Pharma, Inc. today announced that it has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc..

4 Aug 2010

National Research acquires OCS through stock purchase agreement

National Research Corporation today announced it has acquired, via stock purchase agreement, Outcome Concept Systems, Inc., a privately-held healthcare informatics firm, in an all-cash transaction.

4 Aug 2010

Masimo second-quarter product revenue increases 25.6% to $88.0 million

Masimo Corporation, today announced its financial results for the second quarter of 2010.

4 Aug 2010

Biomedical engineering professor receives patent for Electromagnetic Probe Device

The United States Patent Office has issued a patent to Dr. Mark DeCoster, associate professor of biomedical engineering at Louisiana Tech University, for his invention of an "Electromagnetic Probe Device" - an innovative technology developed at Louisiana Tech's Institute for Micromanufacturing.

4 Aug 2010

GE and Intel create new health IT venture focused on home-based care

General Electric Co. and Intel Corp. announced Monday they will create a company to provide new medical technologies for the elderly and chronically ill.

4 Aug 2010

Spectrum Health selects Aternity FPI Platform for strategic end user experience management initiatives

Aternity Inc., the industry's technology leader in end user experience management solutions for Global 1000 enterprises, announced today that Spectrum Health, a not-for-profit health system in West Michigan that offers a full continuum of care that includes the Spectrum Health Hospital Group, has selected the Aternity Frontline Performance Intelligence (FPI) Platform for its strategic end user experience management initiatives.

4 Aug 2010

New algorithm to reduce radiation dose in CT imaging

In recent years, advances in CT scanner technology have made perfusion computed tomography (CT) imaging an important diagnostic tool for patients with suspected stroke. Now, researchers at Mayo Clinic are working to reduce radiation dosages used to acquire perfusion and other CT images. Mayo Clinic medical physicist Cynthia McCollough, Ph.D., and her group of researchers presented their findings related to CT dose reduction at the 52nd Annual Meeting of the American Association of Physicists in Medicine on July 20 in Philadelphia. The presentation was entitled "20-Fold Dose Reduction Using a Gradient Adaptive Bilateral Filter: Demonstration Using in Vivo Animal Perfusion CT."

4 Aug 2010

BARDA awards contract to develop Pfenex Expression Technology

Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has awarded Pfenex a contract providing for up to a total of $18.8 million in funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government. The contract will support the development of a robust Pfenex Expression Technology based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax.

4 Aug 2010